Bridging Science and Strategy: Medical Affairs at the Heart of Omnichannel Engagement

In this video podcast hosted by Pharmaphorum, Editor in Chief Jonah Comstock speaks with Cheryl Lubbert, co-founder and CEO of Reverba Global, and Carolyn Whiting, SVP of Clinical and Medical Client Services. They discuss Reverba Global’s approach to true omnichannel patient and physician engagement, giving examples and insights on how they are overcoming the challenges…

|

In this video podcast hosted by Pharmaphorum, Editor in Chief Jonah Comstock speaks with Cheryl Lubbert, co-founder and CEO of Reverba Global, and Carolyn Whiting, SVP of Clinical and Medical Client Services.

They discuss Reverba Global’s approach to true omnichannel patient and physician engagement, giving examples and insights on how they are overcoming the challenges and building this new paradigm. Tune in to find out how this approach can help your organisation build better connections with patients and HCPs.

Watch here:Bridging Science and Strategy

The Latest

  • Cheryl Lubbert, CEO of Reverba Global, Named 2026 HBA Luminary Award Honoree
    Cheryl Lubbert, CEO of Reverba Global, Named 2026 HBA Luminary Award Honoree

    Cheryl Lubbert, CEO of Reverba Global, has been named a 2026 HBA Luminary Award honoree by the Healthcare Businesswomen’s Association. The recognition reflects her leadership in advancing scientific engagement and…

  • Perspective From Patients as Partners: Sustaining Patient Engagement Through Organizational Changes
    Perspective From Patients as Partners: Sustaining Patient Engagement Through Organizational Changes

    At Patients as Partners 2026, CEO Cheryl Lubbert shared how sustaining patient engagement through organizational change requires intentional design, with systems built to hold as teams, priorities, and programs shift.

  • Pharma USA 2026: AI Scales Reach in Pharma. But What Actually Changes Patient and HCP Behavior?
    Pharma USA 2026: AI Scales Reach in Pharma. But What Actually Changes Patient and HCP Behavior?

    AI is becoming a baseline expectation in pharma. At Pharma USA 2026, discussions reflected less focus on whether AI should be used and more on how it is being applied…

See More Insights